Is Tenable Stock a Buy, Sell or Hold?
Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…
Sell
30
JANX Quote, Financials, Valuation and Earnings
Last price:
$30.04
Seasonality move
:
-8.79%
Day range:
$29.77 - $30.56
52-week range:
$28.92 - $71.71
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
123.32x
P/B ratio:
1.73x
Volume:
1.5M
Avg. volume:
875.1K
1-year change:
-24.87%
Market cap:
$1.8B
Revenue:
$10.6M
EPS (TTM):
-$1.28
Analysts' Opinion
-
Consensus RatingJanux Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $87.85, Janux Therapeutics has an estimated upside of 189.55% from its current price of $29.94.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $29.94.
Fair Value
-
According to the consensus of 13 analysts, Janux Therapeutics has 189.55% upside to fair value with a price target of $87.85 per share.
JANX vs. S&P 500
-
Over the past 5 trading days, Janux Therapeutics has underperformed the S&P 500 by -2.91% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Janux Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Janux Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Janux Therapeutics reported revenues of $439K.
Earnings Growth
-
Janux Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Janux Therapeutics reported earnings per share of -$0.36.
Enterprise value:
744.4M
EV / Invested capital:
--
Price / LTM sales:
123.32x
EV / EBIT:
--
EV / Revenue:
57.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-16.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-10.65%
Net Income Margin (TTM):
-463.91%
Return On Equity:
-11.37%
Return On Invested Capital:
-11.37%
Operating Margin:
-8164.47%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $8.6M | $8.1M | -- | $2.5M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$67.1M | -$73M | -$98.8M | -$16.1M | -$29M | |
| EBITDA | -$66.3M | -$71M | -$96.8M | -$15.6M | -$28.5M | |
| Diluted EPS | -$1.52 | -$1.33 | -$1.28 | -$0.24 | -$0.36 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16.1M | $377M | $332.4M | $349.2M | $1B | |
| Total Assets | $16.2M | $379.8M | $364M | $380.4M | $1.1B | |
| Current Liabilities | $3.2M | $12.8M | $16.5M | $13M | $17.5M | |
| Total Liabilities | $30.9M | $13.5M | $43.3M | $36.1M | $38.7M | |
| Total Equity | -$14.6M | $366.3M | $320.7M | $344.3M | $1B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$42.9M | -$50.6M | -$43.8M | -$9.9M | -$16.7M | |
| Cash From Investing | $58.3M | -$41.2M | -$258M | $11.1M | $33.9M | |
| Cash From Financing | $500K | $59.5M | $713.2M | $831K | $386.7M | |
| Free Cash Flow | -$49.4M | -$52.4M | -$44.2M | -$10.4M | -$16.8M | |
JANX
Sector
Market Cap
$1.8B
$39.2M
Price % of 52-Week High
41.75%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
-13.46%
-0.81%
1-Year Price Total Return
-24.87%
-38.63%
Beta (5-Year)
--
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$30.95
200-day SMA
Sell
Level
$45.30
Bollinger Bands (100)
Sell
Level
36.23 - 56.59
Chaikin Money Flow
Sell
Level
-25.3M
20-day SMA
Sell
Level
$31.74
Relative Strength Index (RSI14)
Sell
Level
35.60
ADX Line
Sell
Level
24.23
Williams %R
Neutral
Level
-70.5202
50-day SMA
Sell
Level
$38.24
MACD (12, 26)
Sell
Level
-2.34
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
4.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (49.5218)
Buy
CA Score
(Annual)
Level (0.9793)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.2131)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
Stock Forecast FAQ
In the current month, JANX has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The JANX average analyst price target in the past 3 months is $87.85.
-
Where Will Janux Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Janux Therapeutics share price will rise to $87.85 per share over the next 12 months.
-
What Do Analysts Say About Janux Therapeutics?
Analysts are divided on their view about Janux Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Janux Therapeutics is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Janux Therapeutics's Price Target?
The price target for Janux Therapeutics over the next 1-year time period is forecast to be $87.85 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is JANX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Janux Therapeutics is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JANX?
You can purchase shares of Janux Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Janux Therapeutics shares.
-
What Is The Janux Therapeutics Share Price Today?
Janux Therapeutics was last trading at $30.04 per share. This represents the most recent stock quote for Janux Therapeutics. Yesterday, Janux Therapeutics closed at $29.94 per share.
-
How To Buy Janux Therapeutics Stock Online?
In order to purchase Janux Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 20
Regencell Bioscience Holdings [RGC] is down 0% over the past day.
Sell
36
VMI alert for Mar 20
Valmont Industries [VMI] is down 0% over the past day.
Buy
61
ALNY alert for Mar 20
Alnylam Pharmaceuticals [ALNY] is down 0% over the past day.
